Precision Immunosuppression in a Carefully Selected Liver Transplant Population: Can MMF Alone “Hold the Fort “?
Authors:
- 2 July 2025
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (6) , 1071-1075
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Mycophenolate Mofetil Monotherapy in Patients Who Underwent Liver Transplantation for Hepatitis C CirrhosisTransplantation Proceedings, 2008
- Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertensionLiver Transplantation, 2006
- Immunosuppression based on mycophenolate mofetil in stable liver transplanted patientsInternational Immunopharmacology, 2006
- Mycophenolate Mofetil Monotherapy in Liver TransplantationTransplantation Proceedings, 2005
- Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experienceLiver Transplantation, 2004
- Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantationTransplantation Proceedings, 2003
- Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantationTransplantation, 2003
- Mycophenolate mofetil monotherapy in liver transplantationThe Lancet, 2001
- Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled studyThe Lancet, 2001
- MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENTTransplantation, 1999